Patent ID: 8859574

Claim:
A method for treating an IGF-1R-mediated condition in a mammal suffering therefrom, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (3) or a pharmaceutically acceptable salt thereof, and optionally in combination with a second therapeutic agent; a pharmaceutically acceptable salt thereof, or a tautomer thereof; wherein ring E may optionally contain a double bond; wherein R 5b is H; and R 5a and R 5c are independently halo, C 1-6 alkyl, C 1-6 alkoxy, halo-substituted C 1-6 alkyl, cyano or C(O)O 0-1 R 8 ; Z 1 and Z 2 are CH 2 ; Z 3 is NR 6 or N(R 6 ) + —O − ; R 1 is halo or an optionally halogenated C 1-6 alkyl; R 3 and R 4 are each H; R 6 is a radical selected from formula (a), (b), (c) or (d): L is (CR 2 ) 1-4 or a bond; wherein R is independently H or C 1-6 alkyl; R 10 is O, S, NR 17 wherein R 17 is H, C 1-6 alkyl, SO 2 R 8a or CO 2 R 8a and R 8a is C 1-6 alkyl; R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are independently selected from H; C 1-6 alkoxy; C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which may be optionally substituted with halo, amino or hydroxyl groups; or R 11 and R 12 , R 12 and R 15 , R 15 and R 16 , R 13 and R 14 , or R 13 and R 15 together with the atoms to which they are attached may form a 3-7 membered saturated, unsaturated or partially unsaturated ring containing 1-3 heteroatoms selected from N, O and S, and optionally substituted with oxo and 1-3 R 5 groups; wherein R 5 is halo, hydroxyl, C 1-6 alkyl, C 1-6 alkoxy, halo-substituted C 1-6 alkyl, halo-substituted C 1-6 alkoxy, cyano or C(O)O 0-1 R 8 ; and R 8 is C 1-6 alkyl; wherein said condition is breast cancer or neuroblastoma.